Drug intelligence / Profile preview

SK16

Development stage: Preclinical
Lead developer: Zhiyi Pharmaceutics
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral, Topical

Overview

SK16 is a preclinical-stage live biotherapeutic product (LBP) being developed by Zhiyi Pharmaceutics for the treatment of oral mucositis. As an LBP, SK16 consists of a specific bacterial strain intended to modulate the oral microbiome and provide anti-inflammatory effects to mitigate mucosal damage, which is often a side effect of chemotherapy or radiation therapy. The program is currently in the preclinical development phase, with the sponsor targeting an Investigational New Drug (IND) application submission in the fourth quarter of 2028.

Beyond the preview

Go deeper on SK16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK16.

Explore the full profile